Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia.
The enzyme xanthine oxidase (XO) has been implicated in the pathogenesis of several disease processes, such as ischemia-reperfusion injury, because of its ability to generate reactive oxygen species. The expression of XO and its precursor xanthine dehydrogenase (XDH) is regulated at pre- and posttranslational levels by agents such as lipopolysaccharide and hypoxia. Posttranslational modification of the protein, for example through thiol oxidation or proteolysis, has been shown to be important in converting XDH to XO. The possibility of posttranslational modification of XDH/XO through phosphorylation has not been adequately investigated in mammalian cells, and studies have reported conflicting results. The present report demonstrates that XDH/XO is phosphorylated in rat pulmonary microvascular endothelial cells (RPMEC) and that phosphorylation is greatly increased ( approximately 50-fold) in response to acute hypoxia (4 h). XDH/XO phosphorylation appears to be mediated, at least in part, by casein kinase II and p38 kinase as inhibitors of these kinases partially prevent XDH/XO phosphorylation. In addition, the results indicate that p38 kinase, a stress-activated kinase, becomes activated in response to hypoxia (an approximately 4-fold increase after 1 h of exposure of RPMEC to hypoxia) further supporting a role for this kinase in hypoxia-stimulated XDH/XO phosphorylation. Finally, hypoxia-induced XDH/XO phosphorylation is accompanied by a 2-fold increase in XDH/XO activity, which is prevented by inhibitors of phosphorylation. In summary, this study shows that XDH/XO is phosphorylated in hypoxic RPMEC through a mechanism involving p38 kinase and casein kinase II and that phosphorylation is necessary for hypoxia-induced enzymatic activation.
Kayyali
U S
US
Department of Medicine, Pulmonary and Critical Care Division, Tupper Research Institute, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Donaldson
C
C
Huang
H
H
Abdelnour
R
R
Hassoun
P M
PM
D000818:Animals; D018053:Arsenites / Q000494:pharmacology; D015153:Blotting, Western; D047390:Casein Kinase II; D002478:Cells, Cultured; D004591:Electrophoresis, Polyacrylamide Gel; D004730:Endothelium, Vascular / Q000378:metabolism; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000860:Hypoxia; D007202:Indicators and Reagents / Q000494:pharmacology; D008168:Lung / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011233:Precipitin Tests; D011499:Protein Processing, Post-Translational; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction; D017670:Sodium Compounds / Q000494:pharmacology; D013012:Sorbitol / Q000494:pharmacology; D014968:Xanthine Dehydrogenase / Q000737:chemistry / Q000378:metabolism*; D014969:Xanthine Oxidase / Q000737:chemistry / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases
D018053:Arsenites; D004791:Enzyme Inhibitors; D007202:Indicators and Reagents; D017670:Sodium Compounds; C017947:sodium arsenite; D013012:Sorbitol; D014968:Xanthine Dehydrogenase; D014969:Xanthine Oxidase; D047390:Casein Kinase II; D017346:Protein Serine-Threonine Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases